| Literature DB >> 24676227 |
Erhan Tenekecioglu1, Fahriye Vatansever Agca1, Ozlem Arican Ozluk1, Kemal Karaagac1, Serafettin Demir2, Tezcan Peker1, Mustafa Kuzeytemiz1, Muhammed Senturk1, Mustafa Yilmaz1.
Abstract
BACKGROUND: Hypertension is the most prevalent and modifiable risk factor for atrial fibrillation. The pressure overload in the left atrium induces pathophysiological changes leading to alterations in contractile function and electrical properties.Entities:
Mesh:
Year: 2014 PMID: 24676227 PMCID: PMC3987319 DOI: 10.5935/abc.20140009
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Demographic and Biochemical Characteristics of Study Groups
|
|
|
|
|
|---|---|---|---|
| Number of subjects | 30 | 27 | 30 |
| Men/women | 16/14 | 15/12 | 17/13 |
| Age (years) | 53 ± 5 | 52 ± 7 | 53 ± 9 |
| Systolic blood pressure (mmHg) | 120 ± 6 | 153 ± 8[ | 154 ± 11[ |
| Diastolic blood pressure (mmHg) | 85 ± 6 | 86.4 ± 7 | 85.3 ± 6 |
| Duration of hypertension (year) | 4.3 ± 1.1 | 7.4 ± 3.1 [ | |
|
| |||
| ACEI/ARB | 4(%15) | 5(%16) | |
| Beta-blockers | 6(%22) | 6(%20) | |
| Calcium-blockers | 7(%26) | 8(%26) | |
| Diuretics | 10(%37) | 11(%36) | |
| Heart rate (bpm) | 77 ± 5 | 74 ± 3 | 75 ± 5 |
| BMI (kg/m2) | 21.3 ± 2.8 | 23.2 ± 2.4 | 23.4 ± 3.3 |
| Glucose (mg/dL) | 93.4 ± 7.5 | 95.2 ± 3.1 | 96.1 ± 2.9 |
| Total cholesterol (mg/dL) | 189.6 ± 17.2 | 182.4 ± 6.0 | 184.3 ± 8.4 |
| HDL cholesterol (mg/dL) | 45.8 ± 10.2 | 43.8 ± 12.0 | 46.2 ± 11.3 |
| LDL cholesterol (mg/dL) | 116.4 ± 11.3 | 115 ± 11.2 | 118.1 ± 10.5 |
| Triglyceride (mg/dL) | 138.0 ± 37.5 | 134.3 ± 29.0 | 132.8 ± 25.3 |
p < 0.05; compared with normotensive subjects
p<0.01; compared with hypertensive patients without PAF. HT: Hypertension; PAF: Paroxysmal atrial fibrillation; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; BMI: Body mass index.
Echocardiographic Parameters in Study Groups
|
|
|
|
|
|---|---|---|---|
| LVDD (cm) | 4.69 ± 4.6 | 4.74 ± 3.6 | 4.67 ± 3.8 |
| LVSD (cm) | 2.85 ± 0.20 | 2.94 ± 0.32 | 2.83 ± 0.39 |
| IVS Thickness (cm) | 0.95 ± 0.08 | 1.23 ± 0.11[ | 1.28 ± 0.09 |
| EF (%) | 73.3 ± 4.0 | 76.60 ± 6.3 | 77.09 ± 7.2 |
| LVMI (g/m2) | 88.7 ± 9.2 | 128.2 ± 9.2 [ | 135.66 ± 5.2[ |
| LA diameter (cm) | 3.6 ± 0.45 | 4.04 ± 0.25[ | 4.60 ± 0.42 [ |
| LAVImax (mL/m2) | 15 ± 3.5 | 19.37 ± 3.97[ | 24.28 ± 3.59 [ |
| LAVImin (mL/m2) | 7 ± 2 | 6.3 ± 1.2 | 12.4 ± 3.63[ |
| LAVIpreA (mL/m2) | 11.46 ± 3.42 | 14.89 ± 4.09[ | 18.46 ± 7.45[ |
| LATEV (mL) | 8.55 ± 1.44 | 12.08 ± 1.87[ | 13.78 ± 2.07[ |
| LAPEV (mL) | 4.85 ± 1.24 | 6.7 ± 1.1[ | 7.02 ± 1.86[ |
| LAAEV (mL) | 5.87 ± 1.65 | 7.38 ± 2.29[ | 6.11 ± 2.63 |
| LACV (mL) | 27.9 ± 4.6 | 24.8 ± 4.9[ | 25.6 ± 5.1 |
| LATEF (%) | 55.14 ± 7.34 | 62.81 ± 10.31[ | 58.17 ± 9.6 |
| LAPEF (%) | 32.12 ± 5.42 | 27.57 ± 5.71[ | 30.24 ± 12.04[ |
| LAAEF (%) | 35.23 ± 11.52 | 46.44 ± 13.51[ | 37.89 ± 12.58 [ |
| Mitral-E (m/s) | 0.77 ± 0.13 | 0.81 ± 0.18 | 0.98 ± 0.12 [ |
| Mitral-A (m/s) | 0.67 ± 0.09 | 0.93 ± 0.04[ | 0.80 ± 0.22[ |
| E/A | 1.15 ± 0.05 | 0.72 ± 0.15[ | 1.21 ± 0.17 [ |
| Mitral E dec. time (ms) | 197.4 ± 21.2 | 184.5 ± 27.3 | 179.45 ± 32.2 |
| Mitral A dec. time (ms) | 99.5 ± 12.8 | 98.73 ± 21.8 | 113.20 ± 9.4 |
|
| |||
| E' (m/s) | 0.102 ± 0.016 | 0.095 ± 0.024[ | 0.104 ± 0.03 |
| A' (m/s) | 0.088 ± 0.021 | 0.120 ± 0.02[ | 0.091 ± 0.02 [ |
| E/E' ratio | 7.2 ± 1.4 | 8.9 ± 2.1[ | 10.1 ± 2.4[ |
p < 0.05; compared with normotensive group
p < 0.05; compared with hypertensive patients without PAF. HT: Hypertension; PAF: Paroxysmal atrial fibrillation; LVDD: Left ventricular diastolic diameter; LVSD: Left ventricular systolic diameter; IVS: Interventricular septum; EF: Ejection fraction; LVMI: Left ventricle mass index; LA: Left atrial; LAVImax: Indexed maximum left atrial volume; LAVImin: Indexed minimum left atrial volume; LAVIpreA: Indexed preatrial contraction volume; LATEV: Left atrial total emptying volume; LAPEV: Left atrial passive emptying volume; LAAEV: Left atrial active emptying volume; LACV: Left atrial conduit volume; LATEF: Left atrial total ejection fraction; LAPEF: Left atrial passive ejection fraction; LAAEF: Left atrial active ejection fraction.
Figure 1ROC curve analysis for LAVImax in predicting PAF (sen: 80%; spe: 51%; AUC: 0.700).
Figure 2ROC curve analysis for LAAEF in predicting PAF (sen: 74%; spe: 55%; AUC: 0.679).
Figure 3ROC curve analysis for A′ in predicting PAF (sen: 67%; spe: 45%; AUC: 0.654).
Multivariate logistic regression analysis; the influence of PAF and hypertension duration on left atrial volume and function
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| PAF | -2.959 | -2.757 | .008 | |
| HT duration | -.185 | -.830 | .410 | |
|
| ||||
| PAF | -2.514 | -2.221 | .031 | |
| HT duration | -.134 | -.569 | .572 | |
|
| ||||
| PAF | -2.728 | -2.614 | .012 | |
| HT duration | -.137 | -.634 | .529 | |
|
| ||||
| PAF | -.445 | -.519 | .606 | |
| HT duration | -.051 | -.287 | .775 | |
|
| ||||
| PAF | .021 | .591 | .557 | |
| HT duration | -.001 | -.082 | .935 | |
|
| ||||
| PAF | .214 | .306 | .761 | |
| HT duration | .004 | .025 | .980 | |
|
| ||||
| PAF | .096 | 2.171 | .034 | |
| HT duration | -.026 | -2.381 | .021 | |
|
| ||||
| PAF | -.231 | -.285 | .777 | |
| HT duration | -.047 | -.283 | .778 | |
|
| ||||
| PAF | .071 | 1.917 | .060 | |
| HT duration | .001 | .164 | .871 | |
|
| ||||
| PAF | -.398 | -.147 | .884 | |
| HT duration | .216 | .383 | .703 | |
HT: Hypertension; PAF: Paroxysmal atrial fibrillation; LAVImax: Indexed maximum left atrial volume; LAVImin: Indexed minimum left atrial volume; LAPEV: Left atrial passive emptying volume; LAPEF: Left atrial passive ejection fraction; LAAEV: Left atrial active emptying volume; LAAEF: Left atrial active ejection fraction; LATEV; Left atrial total emptying volume; LATEF: Left atrial total ejection fraction; LACV: Left atrial conduit volume.